Actinic keratoses (AKs) are intraepidermal tumours, which result from the proliferation of transformed neoplastic keratinocytes. They are typically induced by chronic exposure to ultraviolet radiation, and can often develop into squamous cell carcinoma (SCC). Six patients, who presented with AKs located on the head, face and chest, were treated with the immune response modifier, imiquimod, as a 5% cream five times per week for up to 8 weeks. The majority of patients experienced mild to moderate side-effects, consisting of erythema, itching and burning. Topical application of imiquimod for 4-8 weeks resulted in complete clearance in all patients. No new or recurrent lesions were observed during a 6-8 month follow-up period.

Bianchi, L., Campione, E., Marulli, G.c., Costanzo, A., Chimenti, S. (2003). Actinic keratosis treated with an immune response modifier: a case report of six patients. CLINICAL AND EXPERIMENTAL DERMATOLOGY, 28(1), 39-41 [10.1046/j.1365-2230.28.s1.13.x].

Actinic keratosis treated with an immune response modifier: a case report of six patients

BIANCHI, LUCA;Campione, E;COSTANZO, ANTONIO;CHIMENTI, SERGIO
2003-01-01

Abstract

Actinic keratoses (AKs) are intraepidermal tumours, which result from the proliferation of transformed neoplastic keratinocytes. They are typically induced by chronic exposure to ultraviolet radiation, and can often develop into squamous cell carcinoma (SCC). Six patients, who presented with AKs located on the head, face and chest, were treated with the immune response modifier, imiquimod, as a 5% cream five times per week for up to 8 weeks. The majority of patients experienced mild to moderate side-effects, consisting of erythema, itching and burning. Topical application of imiquimod for 4-8 weeks resulted in complete clearance in all patients. No new or recurrent lesions were observed during a 6-8 month follow-up period.
2003
Pubblicato
Rilevanza internazionale
Articolo
Esperti anonimi
Settore MED/35 - MALATTIE CUTANEE E VENEREE
English
Con Impact Factor ISI
imiquimod; aminoquinoline derivative; immunological adjuvant; actinic keratosis; adult; aged; article; burning sensation; cancer recurrence; cell proliferation; clinical article; erythema; female; follow up; human; keratinocyte; long term exposure; male; priority journal; pruritus; side effect; squamous cell carcinoma; treatment outcome; tumor localization; ultraviolet radiation; case report; keratosis; middle aged; photosensitivity disorder; topical drug administration; antineoplastic activity; antiviral activity; drug efficacy; administration, topical; keratosis; photosensitivity disorders; treatment outcome
Bianchi, L., Campione, E., Marulli, G.c., Costanzo, A., Chimenti, S. (2003). Actinic keratosis treated with an immune response modifier: a case report of six patients. CLINICAL AND EXPERIMENTAL DERMATOLOGY, 28(1), 39-41 [10.1046/j.1365-2230.28.s1.13.x].
Bianchi, L; Campione, E; Marulli, Gc; Costanzo, A; Chimenti, S
Articolo su rivista
File in questo prodotto:
File Dimensione Formato  
Actinic keratosis treated with an immune response modifier a case...Clinical and Experimental Dermatology, 2003, 28 (Suppl. 1), 39–41.pdf

solo utenti autorizzati

Descrizione: Articolo principale
Licenza: Copyright dell'editore
Dimensione 87.36 kB
Formato Adobe PDF
87.36 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/57005
Citazioni
  • ???jsp.display-item.citation.pmc??? 3
  • Scopus 17
  • ???jsp.display-item.citation.isi??? 13
social impact